Drug Profile


Alternative Names: L-leucine/metformin; Metformin/L-leucine; Metformin/leucine; NS-0100

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuSirt Biopharma
  • Class Antihyperglycaemics; Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 23 Mar 2017 Phase-II development for Type-2 diabetes mellitus is ongoing in USA (PO)
  • 26 Jan 2016 NuSirt Biopharma completes a phase IIa trial in Type-2 diabetes mellitus in USA , (NCT02151461)
  • 25 Jun 2015 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus released by NuSirt Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top